| AR (0–2) | HR (≥3) | Se-1a (%) | Se-2a (%) | Se-3a (%) | NPV −1b (%) | NPV −2b (%) | NPV −3b (%) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n (%) | FIT- | FIT+ | n (%) | FIT- | FIT+ | |||||||
ACN | 9 (2.2) | 7 | 2 | 21 (6.4) | 12 | 9 | 76.7% | 36.7% | 70.0% | 98.0% | 97.0% | 97.9% |
Advanced adenoma | 9 (2.2) | 7 | 2 | 16 (4.9) | 11 | 5 | 72.0% | 28.0% | 64.0% | 98.0% | 97.2% | 97.9% |
CRC | 0 (0) | 0 | 0 | 5 (1.5) | 1 | 4 | 100.0% | 80.0% | 100.0% | 100.0% | 99.8% | 100.0% |
Nonadvanced neoplasia | 64 (15.4) | 52 | 12 | 110 (33.6) | 97 | 13 | 70.1% | 14.4% | 63.2% | 85.4% | 76.9% | 84.9% |
Negative | 342 (82.4) | 291 | 51 | 196 (59.9) | 166 | 30 | Â | Â | Â | Â | Â | Â |
Total | 415 (100) | 350 | 65 | 327 (100) | 275 | 52 | Â | Â | Â | Â | Â | Â |